Global Nafarelin Market Size By Application (Endometriosis, Central Precocious Puberty), By Competitive Landscape, By Geographic Scope And Forecast

Nafarelin Market Size And Forecast

Nafarelin Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2023 to 2030.

The substantial growth of the market is due to the ability of nafarelin to treat endometriosis, central precocious puberty, and menstrual cramps. These conditions are becoming highly common with every individual and need to be treated. This is a driver for the Nafarelin Market which is a synthetic hormone and a gonadotropin-releasing hormone agonist (GnRH agonist). The Global Nafarelin Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Nafarelin Market Definition

Nafarelin is a synthetic hormone as well as a gonadotropin-releasing hormone agonist (GnRH agonist). It is used for the treatment of endometriosis, central precocious puberty, pelvic pain, and menstrual cramps. It comes as a nasal spray and is taken through intranasal administration. It can be administered to both boys as well as girls. It reduces the testosterone hormone in boys and estrogen hormones in girls. During in-vitro fertilization (IVF), nafarelin is administered to control ovary stimulation.

Global Nafarelin Market Overview

The demand for the Nafarelin Market is increasing because of its efficiency to treat endometriosis which affects around 10 to 20 percent of women of childbearing age. It is also used to reduce the testosterone hormone in boys and estrogen hormones in girls to balance out their hormones. Another driver for the market is the use of nafarelin during in In-Vitro Fertilization (IVF). It aids to control ovary stimulation. With the recent rise in IVF globally, there is also a rise in demand for Nafarelin. Nafarelin is also used as a part of transgender hormone therapy which adds to the demand for nafarelin.

Being a synthetic hormone does come with serious side effects which can act as a barrier to the market and decrease the demand in the market. These side effects are vaginal dryness, hot flashes, acne, muscle pain, and breast loss. It has also been noticed that there have been increasing incidences of miscarriage, fetal growth restrictions, and birth defects after using nafarelin. Another issue faced by the use of nafarelin is that it decreases bone density which leads to osteoporosis at a later age. With the increase in awareness of the side effects of nafarelin, there is a decrease in its demand.

Global Nafarelin MarketSegmentation Analysis

The Global Nafarelin Market is Segmented on the basis of Application And Geography.

Nafarelin Market, By Application

• Endometriosis
• Central Precocious Puberty

Based on Application, The market is bifurcated into Endometriosis and Central Precocious Puberty. Endometriosis is a condition faced only by girls whereas central precocious puberty is faced by both boys and girls.

Nafarelin Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, The Global Nafarelin Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market is that of North America since it is the top in leading research activities that use nafarelin. The leading players in the market are also all from North America.

Key Players

The “Global Nafarelin Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc., Shanghai Soho-Yiming Pharmaceuticals Co., Ltd., CPC Scientific Inc., Hangzhou Longshine Bio-Tech Co., Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally. 

Key Developments

• In September 2021, Myovant Sciences and Pfizer Inc. announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe endometriosis pain. MYFEMBREE comprises relugolix, which lowers the amount of estrogen (and other hormones) produced by the ovaries, estradiol (an estrogen), which may lessen the risk of bone loss, and norethindrone acetate (a progestin), which is required when women with uteruses (wombs) take estrogen.
• In October 2021, Debiopharm, a Swiss-based global biopharmaceutical business, and Dexa Medica, a renowned Indonesian pharmaceutical company, announced the launch of triptorelin in Indonesia for the treatment of women suffering from gynecological problems, including endometriosis. Triptorelin, also known as Pamorelin, is a gonadotropin-releasing hormone agonist (GnRH-a) that is widely used to treat women with endometriosis and alleviate pain-related symptoms by generating a low estrogen level. Clinical trials demonstrated that Pamorelin improved pain symptoms compared to placebo, as evidenced by a decrease in the number of endometriotic nodules throughout therapy.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.